Establishing a Risk Model for Diabetic Nephropathy and Addressing the Therapeutic Effect of  Combined Epalrestat- Dapagliflozin Regimen. IJKD [Internet]. 2024 Oct. 18 [cited 2025 Jul. 20];18(05). Available from: https://ijkd.org/index.php/ijkd/article/view/8188